Medtronic's Jason Fontana offers an update on next-generation Symplicity Spyral devices, procedures and a new feature they're ...

Analysts are optimistic about Medtronic (MDT) after the Centers for Medicare and Medicaid Services (CMS) proposed to cover ...

Medtronic and Recor Medical both issued statements supporting new Medicare coverage for their respective renal denervation ...

The patented method uses genetic markers and a weighted algorithm to assess the responsiveness to renal denervation.

CMS proposed Medicare coverage for Medtronic's renal denervation therapy for high blood pressure, signaling a key step toward ...

Medtronic reported that it has begun testing an expansion of its renal denervation approach for dropping stubbornly high ...

PARIS, France—With renal denervation on the cusp of gaining a place in clinical practice for the treatment of hypertension, researchers are looking more closely at other conditions associated with ...

Editor’s Note: This is part 1 of a two-part Healio Exclusive series on renal denervation for hypertension control. Hypertension remains an outsized burden in the U.S. and globally, affecting one ...

When renal denervation was finally put to the test in the 535-patient, sham-controlled SYMPLICITY HTN-3 study, sponsored by Medtronic, there was no significant benefit with the invasive therapy. The ...

Renal denervation seems to be more successful at reducing blood pressure in patients with resistant hypertension when it includes accessory renal arteries, according to new research.

Prof. Azizi: Renal denervation was first launched in 2010 and, with aggressive marketing, very quickly began to be performed everywhere around the world.At the European Society of Cardiology ...

David’s blood pressure was dangerously high until he received specialized care and renal denervation at BIDMC’s Complex Hypertension Clinic. Read his story.